About Multiple Myeloma Multiple myeloma
is a type of blood cancer that arises from plasma cells, a type of white blood cell, which is made in the bone marrow.
This process may slow the over-development of plasma cells in multiple myeloma
patients or cause these dangerous cells to die.
Barlogie's work has led to a median survival rate of more than eight years today for Myeloma Institute patients, compared with a 34 percent five-year survival rate for multiple myeloma
patients, as documented by the NCI between 1995-2001.
The clinical manifestations of multiple myeloma
include bone pain, anemia, hypercalcemia, and renal disease.
We very quickly found out there wasn't a whole lot of information available for multiple myeloma
The Multiple Myeloma
Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma
This multiple myeloma
market epidemiology forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research's (IARC's) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC's Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data.
Doctors noted it could be many years before a vaccine for multiple myeloma
call on women who have received silicone implants and have been diagnosed with MGUS, multiple myeloma
, or other monoclonal gammopathies to report their diagnosis to the FDA.
It is an open label, dose escalation study, in which 13 patients with a confirmed clinical diagnosis of smoldering multiple myeloma
will receive either a 0.
Scope - The Multiple Myleoma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for multiple myeloma
in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China).
chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required.